Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Non-GAAP research and development (R&D) expenses by Quarter
Non-GAAP research and development (R&D) expenses ($M) ($M)
Vertex Pharmaceuticals Non-GAAP research and development (R&D) expenses: $889M in Q2 2026, up 1.2% from a year earlier.
Where the Q2 2026 figure comes from
“|| Non-GAAP research and development expenses | $ | 888.7 | $ | 878.1 | $ | 1,748.0 | $ | 1,757.1”
Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Non-GAAP research and development (R&D) expenses ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-rd
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.